Biom’Up gets FDA nod ahead of schedule for hemostatic bleeding control solution

Biom’Up got an FDA nod for Hemoblast Bellows, a hemostatic bleeding control solution, seven months ahead of schedule.

Biom’Up, a device maker based in France, said the FDA signed off on marketing its Hemoblast Bellows hemostatic product designed to control bleeding during surgery.

The FDA nod was given seven months ahead of schedule following an inspection of Biom’Up’s manufacturing facility by the regulatory agency. Hemoblast Bellows uses patented biopolymers designed to simplify surgical procedures in numerous specialties like spine, cardiothoracic, general, orthopedic and plastic. The product doesn’t require preparation time, mixing or heating and can be used once or several times during the surgery, the company said.

The agency’s premarket approval was based on clinical trials of patients undergoing either cardiothoracic, abdominal or orthopedic (lower limb) surgery. In light of interim results of the trials—93% efficacy at six minutes, versus 74% for the control arm—the Independent Data Monitoring Committee unanimously recommended that the study be stopped prior to the initially scheduled end of this trial and that the application be submitted faster.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are delighted to have achieved it over half a year ahead of our initial schedule,” Etienne Binant, Biom’Up’s CEO, said in a statement. “This performance, which has set a new record in the surgical hemostasis sector for a first PMA, is the result of the extraordinary mobilization of all our teams.”

The company said it expects to begin marketing the product in the U.S. by the summer of 2018.

Suggested Articles

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.